Consortium Costs Debated As BARDA, Industry Discuss Plans For Next Pandemic Response
Executive Summary
BARDA’s consortium approach scrutinized as industry recovers from US Defense Production Act rated orders. Questions of sustainment fees, interruptible commercial activities explored during BioMaC Industry Day call as agency emphasizes need for proven capacity.
You may also be interested in...
For Reauthoring Preparedness Law, Congress Needs Advice On Next Public Health Emergency
House Energy and Commerce members seek input as appropriate mix of incentives for next-generation, public-private ventures remains elusive.
US Lawmakers Seek Next-Pandemic Advice For Renewing Preparedness Law
House bipartisan legislators seek input as the appropriate mix of incentives for next-generation public-private ventures remains elusive.
Greater US FDA And Manufacturer Transparency Recommended As Key to Supply Chain Resilience
Manufacturers could risk losing FDA product approvals if they fail to publicize sourcing and quality information, under new proposals. National Academies expert panel says supply chain transparency – not a pandemic-induced rush to onshoring requirements – provides the framework to mitigate against and respond to drug shortages.